Skip to main content

3 Result(s)

within B. Milojkovic Kerklaan Remove this filter

and

  1. No Access

    Article

    A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

    Introduction E7820 is an orally administered sulfonamide that inhibits alfa-2-integrin mRNA expression. Pre-clinically E7820 showed tumor anti-angiogenic effects in various tumor cell lin...

    B. Milojkovic Kerklaan, S. Slater, M. Flynn, A. Greystoke… in Investigational New Drugs (2016)

  2. No Access

    Article

    Strategies to target drugs to gliomas and CNS metastases of solid tumors

    The treatment for central nervous system metastases of solid tumors and gliomas is limited as the blood–brain barrier (BBB) is an obstacle to systemic therapy. Here, we review the physiochemical properties of ...

    B. Milojkovic Kerklaan, O. van Tellingen, A. D. R. Huitema… in Journal of Neurology (2016)

  3. Article

    Open Access

    Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

    This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of two dosing schedules of oral topotecan in combination with pazopanib in patients with advanced solid ...

    B Milojkovic Kerklaan, M P J Lolkema, L A Devriese, E E Voest… in British Journal of Cancer (2015)

    Download PDF (327 KB) View Article